Inogen makes play in stationary market
GOLETA, Calif. – Inogen has received clearance from the U.S. Food and Drug Administration (FDA) for a home oxygen concentrator called Inogen At Home. The company, better known for its portable oxygen concentrators (POCs), plans to start selling the devices later this year. “Inogen’s release of the Inogen At Home, combined with its Inogen One family of products, positions the company with a complete product portfolio to be able to fulfill the clinical requirements of most oxygen therapy patients,” it states in a press release. “While the Inogen One product line is clinically validated for 24/7 use, the Inogen At Home gives Inogen a compelling solution for nocturnal-only oxygen therapy patients that do not yet require a portable solution, which are estimated to represent 30% of total oxygen patients in the United States.” Features of the Inogen At Home include five liter per minute continuous flow, a weight of 18 pounds and low power consumption.